Previous 10 | Next 10 |
2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...
2023-05-19 08:20:32 ET Foot Locker FL -25% after Q1 earning release . Phio Pharmaceuticals ( PHIO ) -12% . Infobird ( IFBD ) -12% . Alimera Sciences ( ALIM ) -11% . Enveric Biosciences ( ENVB ) -10% . Eledon Pharmaceuticals ( E...
2023-05-18 12:42:08 ET Gainers: Enveric Biosciences ( ENVB ) +112% . Phio Pharmaceuticals ( PHIO ) +46% . WANG & LEE GROUP ( WLGS ) +34% . Alimera Sciences ( ALIM ) +29% . SciPlay Corporation ( SCPL ) +26% . Eltek ( ELT...
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells PR Newswire Data is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MARLBOROUGH, Mas...
2023-05-16 13:08:04 ET Gainers: GD Culture Group Limited ( GDC ) +84% . The Singing Machine Company ( MICS ) +62% . Applied Digital Corporation ( APLD ) +51% . Exela Technologies ( XELA ) +40% . AN2 Therapeutics ( ANTX ) +26% . ...
2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...
2023-05-16 09:01:37 ET Phio Pharma ( NASDAQ: PHIO ) witnessed a significant premarket surge of 28% following its announcement that the U.S. Food and Drug Administration (FDA) had granted clearance for its Investigational New Drug ( IND ) application. This clearance pav...
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas PR Newswire MARLBOROUGH, Mass. , May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company...
2023-05-11 17:28:47 ET Phio Pharmaceuticals press release ( NASDAQ: PHIO ): Q1 GAAP EPS of -$3.15. At March 31, 2023, the Company had cash of $9.0 million as compared with $11.8 million at December 31, 2022. For further details see: Phio Pharmaceuticals GAAP EPS ...
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire MARLBOROUGH, Mass. , May 11, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASY...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...